Use of incretin agents and risk of pancreatic cancer: A population-based cohort study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 3, 2016, Pages 258-265

  Knapen, L M ^a   van Dalem, J ^a   Keulemans, Y C ^b   van Erp, N P ^c   Bazelier, M T ^d   De Bruin, M L ^d   Leufkens, H G M ^d   Croes, S ^a   Neef, C ^a,e   de Vries, F ^a,d,e,f   Driessen, J H M ^a,d,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cohort studies; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1; Incretins; Pancreatic cancer; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; PARACETAMOL; PROTON PUMP INHIBITOR; SULFONYLUREA DERIVATIVE; INCRETIN;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIFESTYLE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX; ADOLESCENT; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED KINGDOM; YOUNG ADULT;

EID: 84957844492     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12605     Document Type: Article

References (47)

1. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-433.
2. Butler PC, Elashoff M, Elashoff R, Gale EAM. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013; 36: 2118-2125.
3. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013; 50: 569-577.
4. Farilla L, Hui H, Bertolotto C et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
5. Ryder RE. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med 2013; 30: 1148-1155.
6. Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic β-cell growth factor receptor. Diabetes 2003; 52: 124-132.
7. Niebisz-Cieślak AB, Karnafel W. Insulin sensitivity in chronic pancreatitis and features of insulin resistance syndrome. Pol Arch Med Wewn 2010; 120: 255-263.
8. Cohen D. Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm. BMJ 2013; 346: f3900.
9. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitu: systematic review and meta-analysis. BMC Endocr Disord 2010; 10: 20.
10. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-2604.
11. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4: 119-145.
12. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
13. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
14. Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab 2014; 16: 1247-1256.
15. Driessen JH, van Onzenoort HA, Henry RM et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone 2014; 68: 124-130.
16. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
17. Lalmohamed A, MacGregor AJ, de Vries F, Leufkens HG, van Staa TP. Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England. PLoS One 2013; 8: e65891.
18. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012; 107: 620-626.
19. Zhang J, Dhakal I, Ning B, Kesteloot H. Patterns and trends of pancreatic cancer mortality rates in Arkansas, 1969-2002: a comparison with the US population. Eur J Cancer Prev 2008; 17: 18-27.
20. Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, Koshiol J. Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol 2014; 179: 731-739.
21. Patai Á, Patai ÁV, Solymosi N, Tulassay Z, Herszényi L. Prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography. Orv Hetil 2015; 156: 715-719.
22. Herreros-Villanueva M, Hijona E, Bañales JM, Cosme A, Bujanda L. Alcohol consumption on pancreatic diseases. World J Gastroenterol 2013; 19: 638-647.
23. Vinklerová I, Procházka M, Procházka V, Urbánek K. Incidence, severity, and etiology of drug-induced acute pancreatitis. Dig Dis Sci 2010; 55: 2977-2981.
24. Kaurich T. Drug-induced acute pancreatitis. Proc (Bayl Univ Med Cent) 2008; 21: 77-81.
25. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39: 709-716.
26. Urbánek K, Vinklerová I, Krystyník O, Procházka V. Acute pancreatitis induced by drugs. In: Rodrigo L, ed. Acute Pancreatitis. Ampthill: InTech, 2012. Available from URL: http://www.intechopen.com/books/acute-pancreatitis/acute-pancreatitis-induced-by-drugs. Accessed 28 December 2015.
27. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
28. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like pepide-1-based therapies. Gastroenterology 2011; 141: 150-156.
29. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-1937.
30. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in Type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173: 534-539.
31. Yu X, Tang H, Huang L, Yang Y, Tian B, Yu C. Exentatide-induced chronic damage of pancreatic tissue in rats. Pancreas 2012; 41: 1235-1240.
32. Nachnani JS, Bulchandani DG, Nookala A et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53: 153-159.
33. Rolin B, Larsen MO, Gotfredsen CF et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: 45-52.
34. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012; 61: 1250-1262.
35. Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology 2011; 141: 20-23.
36. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008; 34(Suppl. 2): S73-S77.
37. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
38. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006; 35: 1301-1308.
39. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receivingacid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989-1998.
40. Horwitz RI, Feinstein AR. The problem of protopathic bias in case-control studies. Am J Med 1980; 68: 255-258.
41. De Bruijn KM, Ruiter R, de Keyser CE, Hofman A, Stricker BH, van Eijck CH. Detection bias may be the main cause of increased cancer incidence among diabetics: results from the Rotterdam Study. Eur J Cancer 2014; 50: 2449-2455.
42. Roberts SE, Akbari A, Thorne K, Atkinson M, Evans PA. The incidence of acute pancreatitis : impact of social deprivation, alcohol consumption, seasonal and demographic factors. Aliment Pharmacol Ther 2013; 38: 539-548.
43. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-987.
44. Halfdanarson TR, Pannala R. Incretins and risk of neoplasia. BMJ 2013; 346: f3750; DOI: 10.1136/bmj.f3750.
45. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systemic review and meta analysis. Am J Gastroenterol 2013; 108: 510-519.
46. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286: 921-929.
47. Cancer Research UK. Pancreatic cancer incidence rates, 2015. Available from URL: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/incidence#heading-One. Accessed 12 November 2015.